Molecular classification and pathogenesis of eosinophilic disorders: 2005 Update

Acta Haematologica

Volumn 114, Issue 1, 2005, Pages 7-25

  Gotlib, Jason ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

Chronic eosinophilic leukemia; Fibroblast growth factor receptor 1; FIP1 like 1 platelet derived growth factor receptor ; Hypereosinophilic syndrome; Platelet derived growth factor receptor

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYDROXYUREA; IMATINIB; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SU 5614; THRX 165724; UNCLASSIFIED DRUG; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME INSERTION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; KARYOTYPE; MAST CELL; MOLECULAR BIOLOGY; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE;

HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MASTOCYTOSIS, SYSTEMIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSLOCATION, GENETIC;

EID: 21344440247     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085559     Document Type: Review

References (191)

1. Hardy WR, Anderson RE: The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-1229.
2. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 1975;54:1-27.
3. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G: Chronic eosinophilic leukaemia and the hypereosinophilic syndrome; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization of Tumours: Tumours of Haematopoietic and Lymphoid tissues. Lyon, IARC Press, 2001, pp 29-31.
4. Roufosse F, Cogan E, Goldman M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004;59:673-689.
5. Forrest DL, Horsman DE, Jensen CL, et al: Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): Confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998;107:65-68.
6. Goldman JM, Najfeld V, Th'ng KH: Agar culture and chromosome analysis of eosinophilic leukaemia. J Clin Pathol 1975;28:956-961.
7. Chang HW, Leong KH, Koh DR, Lee SH: Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999;93:1651-1657.
8. Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G: Clonal nature of hypereosinophilic syndrome. Blood 1994;84:349-350.
9. Schoch C, Reiter A, Bursch S, et al: Chromosome banding analysis, FISH and RT-PCR performed in parallel in hypereosinophilic syndrome establishes the diagnosis of chronic eosinophilic leukemia in 22% of cases: A study on 40 patients (abstract). Blood 2004;104:671a.
10. Pardanani A, Ketterling RP, Brockman SR, et al: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003;102:3093-3096.
11. Tefferi A, Lasho TL, Brockman SR, et al: FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004;89:871-873.
12. Lemery SJ, Robyn JA, McCoy P, et al: Lineage analysis of the FIP1L1-PDGFRa fusion gene in myeloproliferative hypereosinophilic syndrome (abstract). Blood 2004;104:670a-671a.
13. Kawasaki A, Mizushima Y, Matsui S, Hoshino K, Yano S, Kitagawa M: A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report. Tumori 1991;77:527-530.
14. Endo M, Usuki K, Kitazume K, Iwabe K, Okuyama Y, Urabe A: Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 1995;71:313-314.
15. Catovksy D, Bernasconi C, Verdonck PJ, et al: The association of eosinophilia with lymphoblastic leukaemia or lymphoma: A study of seven patients. Br J Haematol 1980;45:523-534.
16. Takai K, Sanada M: Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol 1991;54:231-239.
17. Bain BJ: Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 2003;122:173-179.
18. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
19. Park CY, Chung CH, Park YJ: Chronic eosinophilic leukemia with 46,XY,1,der(1;7)(q10; p10). Ann Hematol 2004;83:547-548.
20. Hermida G, Manjon R, Rodriguez-Salazar M, Calasanz MJ: Hypereosinophilia associated with dysplastic features and a constitutional translocation previously not described. Haematologica 2000;85:997-998.
21. Musto P, Falcone A, Sanpaolo G, et al: Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk Lymphoma 2004;45:1219-1222.
22. Myint H, Chacko J, Mould S, Ross F, Oscier DG: Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation. Br J Haematol 1995;90:462-464.
23. Shanske AL, Kalman A, Grunwald H: A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). Br J Haematol 1996;95:524-526.
24. Duell T, Mittermuller J, Schmelzer HM, Kolb HJ, Wilmanns W: Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32). Cancer Genet Cytogenet 1997;94:91-94.
25. Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B: Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4; 7) aberration. Ann Hematol 2000;79:95-98.
26. Hild F, Fonatsch C: Cytogenetic peculiarities in chronic myelogenous leukemia. Cancer Genet Cytogenet 1990;47:197-217.
27. Bakhshi S, Hamre M, Mohamed AM, Feldman G, Ravindranath Y: t(5;9)(q11;q34): A novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol 2003;25:82-84.
28. Yoo TJ, Orman SV, Patil SR, et al: Evolution to eosinophilic leukemia with a t(5;11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 1984;11:389-394.
29. Suzuki S, Chiba K, Toyoshima N, et al: Chronic eosinophilic leukemia with t(6;11)(q27;q23) translocation. Ann Hematol 2001;80:553-556.
30. Presti C, Ryan T, Armstrong WF: Two dimensional and Doppler echocardiographic findings in hypereosinophilic syndrome. Am Heart J 1987;114:172-175.
31. da Silva MA, Heerema N, Schwenk GR Jr, Hoffman R: Evidence for the clonal nature of hypereosinophilic syndrome. Cancer Genet Cytogenet 1988;32:109-115.
32. Vandenberghe P, Wlodarska I, Michaux L, et al: Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734-742.
33. Kobayashi H, Kitano K, Shimodaira S, et al: Eosinophilia in myelodysplastic syndrome with a t(12;21)(q23;q22) translocation. Cancer Genet Cytogenet 1993;68:95-98.
34. Brito-babapulle F, Butler TA, Seeker-Walker L, Goldman JM: Eosinophilic myelodysplastic syndrome: An entity to be distinguished from the idiopathic hypereosinophilic syndrome (abstract). Blood 1997;90:285b.
35. Ishii Y, Ito Y, Kuriyama Y, Tauchi T, Ohyashiki K: Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leuk Res 2004;28(suppl 1):S79-S80.
36. Bigoni R, Cuneo A, Roberti MG, et al: Cytogenetic and molecular characterization of 6 new cases of idiopathic hypereosinophilic syndrome. Haematologica 2000;85:486-491.
37. Humphrey MJ, Hutter JJ, Tom WW: Hypereosinophilia in a monosomy 7 myeloproliferative disorder in childhood. Am J Hematol 1981;11:107-110.
38. Viniou N, Yataganas X, Abazis D, et al: Hypereosinophilia associated with monosomy 7. Cancer Genet Cytogenet 1995;80:68-71.
39. Maubach PA, Bauchinger M, Emmerich B, Rastetter J: Trisomy 7 and 8 in Ph-negative chronic eosinophilic leukemia. Cancer Genet Cytogenet 1985;17:159-164.
40. Weinfeld A, Westin J, Swolin B: Ph1-negative eosinophilic leukemia with trisomy 8. Scand J Haematol 1977;18:413-420.
41. Parreira L, Tavares de Castro J, Hibbin JA, et al: Chromosome and cell culture studies in eosinophilic leukaemia. Br J Haematol 1986;62:659-669.
42. Michel G, Thuret I, Capodano AM, et al: Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: Response to corticotherapy. Med Pediatr Oncol 1991;19:62-65.
43. Guitard AM, Horschowski N, Mozziconacci MJ, et al: Hypereosinophilic syndrome in childhood: Trisomy 8 and transformation to mixed acute leukaemia. Nouv Rev Fr Hematol 1994;35:555-559.
44. Ribeiro I, Carvalho IR, Fontes M, et al: Eosinophilic leukaemia with trisomy 8 and double gammopathy. J Clin Pathol 1993;48:672-673.
45. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L: Alpha-interferon and hypereosinophilic syndrome with trisomy 8: Karyotypic remission. Blood 1995;85:2284-2285.
46. Ma SK, Kwong YL, Shek TW, et al: The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol 1999;30:864-868.
47. Pardanani A, Reeder T, Porrata L, et al: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-3397.
48. Salem Z, Zalloua PA, Chehal A, et al: Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Leuk Res 2003;4:410-412.
49. Kook H, Cho D, Noh H-Y, et al: Chronic eosinophilic leukemia with unique chromosomal abnormality, add(8)(p23), in a 14-month girl: Treatment with imatinib mesylate (abstract). Blood 2002;100:344b.
50. Egesten A, Hagerstrand I, Kristoffersson U, Garwicz S: Hypereosinophilic syndrome in a child mosaic for a congenital triplication of the short arm of chromosome 8. Br J Haematol 1997;96:369-373.
51. Mori Y, Ebira H, Shindo Y, Saita R, Kitamura H: Eosinophilic leukemia with trisomy no. 8 and no. 9 chromosomes: Report of a case. Rinsho Ketsueki 1986;27:565-569.
52. Kueck BD, Smith RE, Parkin J, Peterson LC, Hanson CA: Eosinophilic leukemia: A myeloproliferative disorder distinct from the hypereosinophilic syndrome. Hematol Pathol 1991;5:195-205.
53. Oliver JW, Deol I, Morgan DL, Tonk VS: Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 1998;107:111-117.
54. Weide R, Rieder H, Mehraein Y, et al: Chronic eosinophilic leukaemia (CEL): A distinct myeloproliferative disease. Br J Haematol 1997;96:117-123.
55. Mitelman F, Panari A, Brandt L: Isochromosome 17 in a case of eosinophilic leukaemia. Scand J Haematol 1975;14:308-312.
56. Cabrol C: Chromosomal anomaly in eosinophilic leukemia. N Engl J Med 1979;301:439.
57. Lönnqvist B, Gahrton G, Erikkson P, Friberg K, Zech L: Isochromosome 17 in a patient with a myeloproliferative disorder terminating in eosinophilic leukemia. Acta Med Scand 1979;206:321-325.
58. Rotoli B, Catalano L, Galderisi M, et al: Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma 2004;45:2503-2507.
59. Brigaudeau C, Liozon E, Bernard P, Trimoreau F, Bordessoule D, Praloran V: Deletion of chromosome 20q associated with hypereosinophilic syndrome. A report of two cases. Cancer Genet Cytogenet 1996;87:82-84.
60. Kusanagi Y, Ochi H, Matsubara K, Ito M: Hypereosinophilic syndrome in a trisomy 21 fetus. Obstet Gynecol 1998;92:701-702.
61. Needleman SW, Mane SM, Gutheil JC, Kapil V, Heyman MR, Testa JR: Hypereosinophilic syndrome with evolution to myeloproliferative disorder: Temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990;4:149-155.
62. Pardanani A, Brockman SR, Paternoster SF, et al: FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiha. Blood 2004;104:3038-3045.
63. Goffman TE, Mulvihill JJ, Carney DN, et al: Fatal hypereosinophilia with chromosome 15q- in a patient with multiple primary and familial neoplasms. Cancer Genet Cytogenet 1983;8:197-202.
64. Flannery EP, Dillon DE, Freeman MV, Levy JD, D'Ambrosio U, Bedynek JL: Eosinophilic leukemia with fibrosing endocarditis and short Y chromosome. Ann Intern Med 1972;77:223-228.
65. Bitran JD, Rowley JD, Plapp F, Golomb HM, Ultmann JE: Chromosomal aneuploidy in a patient with hypereosinophilic syndrome. Evidence for a malignant disease. Am J Med 1977;63:1010-1014.
66. Huang CS, Gomez GA, Kohno SI, et al: Chromosomes and causation of human cancer and leukemia. XXXIV. A case of hypereosinophilic syndrome' with unusual cytogenetic findings in a chloroma, terminating in blastic transformation and CNS leukemia. Cancer 1979;44:1284-1289.
67. Ellman L, Hammond D, Atkins L: Eosinophilia, chloromas, and a chromosome abnormality in a patient with a myeloproliferative syndrome. Cancer 1979;43:2410-2413.
68. Goh KO, Ho FS, Tso SC, Ma J: Is hypereosinophilic syndrome a malignant disease? Cancer 1985;55:2395-2399.
69. Mitter NS, Weiskopf RW: Unusual chromosome 7 aberrations in a case of eosinophilic myeloproliferative syndrome. Cancer Genet Cytogenet 1987;26:209-212.
70. Wolz DE, Granato JE, Giles HR, Marks SM, Grill HP: A unique chromosomal abnormality in idiopathic hypereosinophilic syndrome presenting with cardiac involvement. Am Heart J 1993;126:246-248.
71. Musto P, Perla G, Minervini MM, Carella AM: Imatinib-mesylate for all patients with hypereosinophilic syndrome. Leuk Res 2004;28:773-774.
72. Pardanani A, Reeder T, Li CY, Tefferi A: Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003;27:883-885.
73. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD: Association of inversion 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med 1983;309:630-636.
74. Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JKH, Hayhoe FGJ: 8;21 translocation in acute granulocytic leukemia: Cytological, cytochemical, and clinical features. Br J Haematol 1984;56:199-213.
75. Song HS, Park SK: A case of monosomy-7 eosinophilic leukemia and neurofibromatosis, terminated with disseminated cryptococcosis. Korean J Intern Med 1987;2:131-134.
76. Harrington DS, Peterson C, Ness M, Sanger W, Smith DM, Vaughan W: Acute myelogenous leukemia with eosinophilic differentiation and trisomy-1. Am J Clin Pathol 1988;90:464-469.
77. Broustet A, Bernard P, Dachary D, et al: Acute eosinophilic leukemia with a translocation (10p+;11q-). Cancer Genet Cytogenet 1986;1:327-333.
78. Bhambhani K, Inoue S, Tyrkus M, Gohle N: Acute myelomonocytic leukemia type M4 with bone marrow eosinophilia and t(5;16)(q33; q22). Cancer Genet Cytogenet 1986;20:187-188.
79. Mecucci C, Bosly A, Michaux JL, Broeckaert-Van Orshoven A, Van den Berghe H: Acute nonlymphoblastic leukemia with bone marrow eosinophilia and structural anomaly of chromosome 16. Cancer Genet Cytogenet 1985;17:359-363.
80. Matsushima T, Murakami H, Kim K, et al: Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. Am J Hematol 1995;50:110-115.
81. Reilly JT: Class III receptor tyrosine kinases: Role in leukaemogenesis. Br J Haematol 2002;116:744-757.
82. Yarden Y, Escobedo JA., Kuang W-J, et al: Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986;323:226-232.
83. Yoon SY, Tefferi A, Li CY: Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000;104:151-157.
84. Heldin C-H, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316.
85. Claesson-Welsh L: Platelet-derived growth factor receptor signals. J Biol Chem 1994;269:32023-32026.
86. Li X, Ponten A, Aase K, et al: PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-309.
87. Bergsten E, Uuetela M, Li X, et al: PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-516.
88. LaRochelle WJ, Jeffers M, McDonald WF, et al: PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517-521.
89. Heldin CH, Ostman A, Ronnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79-F113.
90. Valgeirsdottir S, Paukku K, Silvennoinen O, et al: Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene 1998;16:505-515.
91. Sachsenmaier C, Sadowski HB, Cooper JA: STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Oncogene 1999;18:3583-3592.
92. Golub TR, Barker GF, Lovett M, et al: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-316.
93. Abe A, Emi N, Tanimoto M, et al: Fusion of the platelet-derived growth factor beta receptor to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997;90:4271-4277.
94. Ross TS, Bernard OA, Berger R, et al: Fusion of Huntington interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998;91:4419-4426.
95. Schwaller J, Anastasiadou E, Cain D, et al: H4/D10S170, a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001;97:3910-3918.
96. Kulkarni S, Heath C, Parker S, et al: Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL negative myeloproliferative disorders with a t(5; 10)(q33;q21). Cancer Res 2000;60:3592-3598.
97. Magnusson MK, Meade KE, Brown KE, et al: Rabaptin-5 is a novel fusion partner to platelet-derived growth factor receptor beta in chronic myelomonocytic leukemia. Blood 2001;98:2518-2525.
98. Baxter EJ, Kulkarni S, Vizmanos JL, et al: Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003;120:251-256.
99. Wilkinson K, Velloso ER, Lopez LF, et al: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: Involvement of PDGFRB and response to imatinib. Blood 2003;102:4187-4190.
100. Morerio C, Acquila M, Rosanda C, et al: HC-MOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 2004;64:2649-2651.
101. Vizmanos JL, Novo FJ, Roman JP, et al: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a 1(5;14)(q33;q24) and an imatinibresponsive myeloproliferative disorder. Cancer Res 2004;64:2673-2676.
102. Grand FH, Burgstaller S, Kuhr T, et al: P53-binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004;64:7216-7219.
103. Ketterling RP, Knudson RA, Gilmer HCF: Discovery of 6 novel translocations involving the imatinib responsive genes PDGFRA and PDGFRB from screening 29,047 abnormal bone marrow specimens (abstract). Blood 2004;104:793a.
104. Levine RL, Wadleigh M, Sternberg DW, et al: KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005;19:27-30.
105. Steer EJ, Cross NC: Myeloproliferative disorders with translocations of chromosome 5q31-5q35: Role of the platelet-derived growth factor receptor beta. Acta Haematol 2002;107:113-122.
106. Ross TS, Gilliland DG: Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem 1999;274:22328-22336.
107. Baxter EJ, Hochhaus A, Bolufer P, et al: The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002;11:1391-1397.
108. Trempat P, Villalva C, Laurent G, et al: Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: A new clinical target for STI571/Glivec. Oncogene 2003;22:5702-5706.
109. Safley AM, Sebastian S, Collins TS, et al: Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 2004;40:44-50.
110. Schaller JL, Burkland GA: Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001;3:9.
111. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH: Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002;359:1577-1578.
112. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26:881-884.
113. Nolasco I, Carvalho S, Parreira A: Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia (abstract). Blood 2002;100:346b.
114. Cortes J, Ault P, Koller C, et al: Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101:4714-4716.
115. Preker PJ, Lingner J, Minvielle-Sebastia L, Keller W: The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase. Cell 1995;81:379-389.
116. Martinelli G, Cilloni D, Ottaviani E, et al: Idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement can be effectively treated with imatinib (abstract). Blood 2004;104:421a.
117. Martinelli G, Apperley J, Reiter A, et al: European multicenter experience on idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement treated with imatinib (abstract). Blood 2004;104:422a.
118. Roche-Lestienne C, Soenen-Cornu V, Kahn J-E, et al: Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics (abstract). Blood 2004;104:671a.
119. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003;100:7830-7835.
120. Cools J, Quentmeier H, Huntly BJP, et al: The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004;103:2802-2805.
121. Gotlib J, Cools J, Malone JM, et al: The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004;103:2879-2891.
122. Walz C, Cilloni D, Soverini S, et al: Molecular heterogeneity of the FIP1L1-PDGFRA fusion gene in chronic eosinophilic leukemia (CEL) and systemic mastocytosis with eosinophilia (SME): A study of 43 cases (abstract). Blood 2004;104:667a.
123. Zhang GS, Li B, Pei MF, et al: Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome. Zhonghua Yi Xue Za Zhi 2004;84:1541-1544.
124. Yu J, Deuel TF, Kim HR: Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta-induced phenotypic transformation. J Biol Chem 2000;275:19076-19082.
125. Yang J, Symes K, Mercola M, Schreiber SL: Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol 1998;8:11-18.
126. Stover EH, Cools J, Gilliland DG: Mechanisms of activation of the FIP1L1-PDGFRα fusion kinase (abstract). Blood 2004;104:666a.
127. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-1542.
128. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations in c-kit in human gastrointestinal tumors. Science 1998;279:577-580.
129. Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D: Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem 2002;277:38627-38634.
130. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
131. Klion AD, Robyn J, Akin C, et al: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-478.
132. Malagola M, Martinelli G, Rondoni M, et al: Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. Haematologica 2004;89:ECR25.
133. Martinelli G, Malagola M, Ottaviani E, et al: Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome. Haematologica 2004;89:236-237.
134. Rose C, Dupire S, Roche-Lestienne C, et al: Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia 2004;18:354-355.
135. Frickhofen N, Marker-Hermann E, Reiter A, et al: Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol 2004;83:477-480.
136. Von Bubnoff N, Sandherr M, Schlimok G, et al: Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005;19:286-287.
137. Cools J, Stover EH, Boulton CL, et al: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease. Cancer Cell 2003;3:459-469.
138. Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-4666.
139. Keene P, Mendelow B, Pinto MR, et al: Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A non-random association. Br J Haematol 1987;67:25-31.
140. Greipp PT, Dewald GW, Tefferi A: Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genet Cytogenet 2004;153:170-172.
141. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
142. Pitini V, Arrigo C, Teti D, et al: Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: A new case report. Haematologica 2003;88:ECR18.
143. Wittman B, Horan J, Baxter J, et al: A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leuk Res 2004;28(suppl 1):S65-S69.
144. Garcia JL, Font de Mora J, Hernandez JM, et al: Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 2003;102:2699-2700.
145. Bastie JN, Garcia I, Terre C, et al: Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica 2004;89:1263-1264.
146. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood 2002;100:1088-1091.
147. Sato H, Danbara M, Tamura M, Morita M: Eosinophilic leukemia with a t(2;5)(p23;q35) translocation. Br J Haematol 1994;87:404-406.
148. Darbyshire PJ, Shortland D, Swansbury GJ, Sadler J, Lawler SD, Chessells JM: A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation. Br J Haematol 1987;66:483-486.
149. Jani K, Kempski HM, Reeves BR: A case of myelodysplasia with eosinophilia having a translocation t(5;12)(q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol 1994;87:57-60.
150. Cools J, Mentens N, Odero MD, et al: Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002;99:1776-1784.
151. Yoneda-Kato N, Look AT, Kirstein MN, et al: The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996;12:265-275.
152. Borkhardt A, Bojesen S, Haas OA, et al: The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000;97:9168-9173.
153. Taki T, Kano H, Taniwaki M, et al: AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13a23). Proc Natl Acad Sci USA 1999;96:14535-14540.
154. Jaju RJ, Fidler C, Haas OA, et al: A novel gene, NSD1, is fused to NUP98 in the t(5; 11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001;98;1264-1267.
155. Yagasaki F, Jinnai I, Yoshida S, et al: Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 1999;26:192-202.
156. Meeker TC, Hardy D, Willman C, Hogan T, Abrams J: Activation of the interleukin-3 gene by chromosome translocation in acute lymphoblastic leukemia with eosinophilia. Blood 1990;76:285-289.
157. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M: Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13) and ETV6-ABL gene rearrangement: Case report and review of the literature. Cancer Genet Cytogenet 2002;138:139-142.
158. La Starza R, Trubia M, Testoni N, et al: Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002;87:789-794.
159. Cazzaniga G, Tosi S, Aloisi A, et al: The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo with a t(1;12) (q25;p13): Molecular cloning of both reciprocal transcripts. Blood 1999;94:4370-4373.
160. Kuno Y, Abe A, Emi N, et al: Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood 2001;97:1050-1055.
161. Macdonald D, Reiter A, Cross NCP: The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002;107:101-107.
162. Popovici C, Adelaide J, Ollendorff V, et al: Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 1998;95:5712-5717.
163. Reiter A, Sohal J, Kulkarni S, et al: Consistent fusion of ZNF198 to the fibroblast growth factor receptor 1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998;92:1735-1742.
164. Smedley D, Hamoudi R, Clark J, et al: The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 1998;7:637-642.
165. Xiao S, Nalabolu SR, Aster JC, et al: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998;18:84-87.
166. Popovici C, Zhang B, Gregoire MJ, et al: The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999;93:1381-1389.
167. Guasch G, Mack GJ, Popovici C, et al: FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000;95:1788-1796.
168. Demiroglu A, Steer EJ, Heath C, et al: The t(8:22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001;98:3778-3783.
169. Fioretos T, Panagopoulos I, Lassen C, et al: Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 2001;32:302-310.
170. Guasch G, Popovici C, Mugneret F, et al: Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 2003;101:286-288.
171. Grand EK, Grand FH, Chase AJ, et al: Identification of a novel gene. FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2004;40:78-83.
172. Belloni E, Trubia M, Gasparini P, et al: 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 2005;42:320-325.
173. Sohal J, Chase A, Mould S, et al: Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 2001;32:155-163.
174. Mason IJ: The ins and outs of fibroblast growth factors. Cell 1994;78:547-552.
175. Ollendorff V, Guasch G, Isnardon D, et al: Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem 1999;274:26922-26930.
176. Smedley D, Demiroglu A, Abdul-Rauf M, et al: ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATs 1 and 5. Neoplasia 1999;1:349-355.
177. Roumiantsev S, Krause DS, Neumann CA, et al: Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004;5:287-298.
178. Chen J, DeAngelo DJ, Kutok JL, et al: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:14479-14484.
179. Rothenberg ME: Eosinophilia. N Engl J Med 1998;338:1592-1600.
180. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M: Brief report: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-538.
181. Simon HU, Yousefi S, Dommann-Scherrer CC, et al: Expansion of cytokine-producing CD4-CD8-T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-1082.
182. Brugnoni D, Airo P, Rossi G, et al: CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996;87:1416-1422.
183. Roufosse F, Schandene L, Sibille C, et al: T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood 1999;94:994-1002.
184. Bank I, Amariglio N, Reshef, A, et al: The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma 2001;42:123-133.
185. Simon HU, Plotz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic hypereosinophilia. N Engl J Med 1999;341:1112-1120.
186. Brugnoni D, Airo P, Tosoni C, et al: CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia 1997;11:1983-1985.
187. Roufosse F, Schandene L, Sibille C, et al: Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000;109:540-548.
188. Kitano K, Ichikawa N, Shimodaira S, et al: Eosinophilia associated with clonal T-cell proliferation. Leuk Lymphoma 1997;27:335-342.
189. Roumier AS, Grardel N, Lai JL, et al: Hypereosinophilia with abnormal T cells, trisomy 7, and elevated TARC serum level. Haematologica 2003;88:ECR24.
190. Bassan R, Locatelli G, Borleri G, Salvi A, Barbui T: Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. Haematologica 2004;89:238-239.
191. DeLavareille A, Roufosse F, Schmid-Grendelmeier P, et al: High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002;110:476-479.